Mikael Thomsen

Mikael has worked in the pharmaceutical area for close to 20 years within different major pharmaceutical companies including Novartis Pharma, Basel, Switzerland, and Novo Nordisk, as well as at the U.S. Food and Drug Administration. He is co-founder of the Biotech company OSI Prosidion Ltd, Oxford, UK where he acted as the VP of Development for more than three years bringing several drug candidates from Research to clinical Phase IIa. He has functioned as Chief Development Officer in the German biotech, Probiodrug AG as well as Chief Scientific Officer and Head of R&D in Bridge BioResearch, a UK/Danish-based biotech. He co-founded the Danish biotech company Sound Biotech as well as, Concit Pharma (Contera Pharma) and Conrig Pharma. Contera Pharma acquired by Bukwang Pharm. Co., Ltd 2014. He is an experienced Clinical Pharmacologist who was responsible for planning and conducting Phase 1/2 activities (clinical development plans and trials) as well as he managed several projects through the regulatory pre-clinical and CMC phase leading to clinical activities.